Obesity. Obesity, unspecified
Conditions
Interventions
Interventional group: 75 individuals with class 1, 2, or 3 obesity (Body Mass Index greater than or equal to 30) (25 people per level), aged 18 to 60 years, were enrolled in the study at the Kosar Edu
Sponsors
Semnan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Overweight, grade 1, 2 and 3 obesity (BMI=30) aged 18 to 60 years Constant body weight (less than 5% change in the previous 3 months)
Exclusion criteria
Exclusion criteria: People with kidney disease Pregnant and lactating mothers People with a history of eating disorders such as bulimia nervosa History of pancreatitis Using other medications that affect weight loss in the last three months (such as orlistat, phentermine and topiramate, bupropion, and naltrexone) or any medication with a central effect Use of medications that cause weight gain Previous bariatric surgery History of depression or psychiatric disorders Thyroid diseases Type 1 and Type 2 diabetes Smokers People who drink alcohol Unbearable reaction to drug side effects History of Medullary Thyroid Carcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body Mass Index. Timepoint: Before starting the intervention, 28 days and 84 days after beginning the use of liraglutide branded as Maciza. Method of measurement: Measuring weight with a scale accurate to 100 grams, in units of kilograms, and dividing it by the square of the patient's height measured with an accuracy of 1 centimeter, in units of meters. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hypoglycemia and Blood Glucose level. Timepoint: During the first 84 days of medication use. Method of measurement: Glucometer.;Nausea and Vomiting. Timepoint: During the first 84 days of medication use. Method of measurement: Based on the individual's statement.;Abdominal pain related to medication. Timepoint: During the first 84 days of medication use. Method of measurement: Based on the individual's statement.;Diarrhea related to medication consume. Timepoint: During the first 84 days of medication use. Method of measurement: Based on the individual's statement.;Constipation. Timepoint: During the first 84 days of medication use. Method of measurement: Based on the individual's statement.;Urticaria. Timepoint: During the first 84 days of medication use. Method of measurement: Examination.;Headache. Timepoint: During the first 84 days of medication use. Method of measurement: Based on the individual's statement, with no other reason being presented.;Diziness and weakness. Timepoint: During the first 84 days of medication use. Method of measurement: Based on the individual's statement, with no other reason being presented.;Patient tolerance to medication. Timepoint: During the first 84 days of medication use. Method of measurement: The percentage of patients who completely take their medication as prescribed for three months. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Abolfazl Fattah
Semnan University of Medical Sciences
Outcome results
None listed